

NORTH AMERICAN MICROBIOME CONGRESS

5-7 February
HILTON SAN DIEGO RESORT
San Diego, USA

BENEFITS OF ATTENDING



ONE-TO-ONE MEETINGS

Forge relationships for future research collaborations and business partnering opportunities with the dedicated one-to-one meetings.



METHODOLOGIES

Navigate the benefits and challenges of methods such as metagenomics and metabolomics in determining a healthy microbiome and its functional interactions with the host.



NOVEL & UNPUBLISHED DATA

Review novel and unpublished data, new technological advances and translational case studies to inform your future research.



POSTER SESSION

Actively contribute to inspiration and innovation in microbiome research by submitting a poster to the dedicated poster presentation.



INVESTMENT CRITERIA

Discover how investors and pharmaceutical companies evaluate potential investments, and understand how to commercialized your innovation and IP into a viable business.



TRANSLATE RESEARCH

Discuss and develop approaches to translate academic research into clinically and commercially viable nutritional, diagnostic and therapeutic solutions.

Active Contributors WANTED



We understand that inspiration & innovation in **Translating Academic Research into Clinically and Commercially Viable Therapeutics** comes from connecting ideas... and a truly engaging onsite experience.

Innovation
Stage

APPLY NOW ▶

Poster
Presentation

SUBMIT NOW ▶

Rising Star
Travel Grants

SUBMIT NOW ▶

Commercialization
Surgery

SUBMIT NOW ▶

Meeting Mojo.
One-to-One Meeting
Scheduler

REGISTER NOW ▶

150
ACADEMICS
AND INDUSTRY
Leaders Onsite

30+
THOUGHT
LEADERS
on the Speaker
Faculty

50:50
RATIO
of Academics
to Industry

19
ONE-TO-ONE
Private Meetings
per Attendee

The Onsite EXPERIENCE



"Lots of valuable insights and rich one-to-one exchanges"

Co Founder, Gnubiotics Sciences

2017

SPEAKER FACULTY



Jim Weston
Vice President
and Head of
Regulatory Affairs
Seres Therapeutics



Sarkis K.
Mazmanian
Professor of Microbiology;
Investigator, Heritage
Medical Research
Institute. B.S.
**University of
California**



David H.
Donabedian
Co-founder & CEO
Axial Biotherapeutics



Mary Regan
Associate Professor
**University of
Maryland School of
Nursing**



David Sela
Assistant Professor in
the Department of Food
Science
**University of
Massachusetts**



Rebecca Santelli
Associate Professor
UNC School of Medicine



Maria Marco
Associate Professor,
Food Science and
Technology
UC Davis



David Kyle
Chairman of the Board,
Chief Scientific Officer
Evolve Biosystems



Bruce Taillon
Director External
Innovation
Elanco



Janet Jansson
Division Director of
Biological Sciences
**Pacific Northwest
National Laboratory**



Susan Lynch
Director, Colitis and Crohn's
Disease Microbiome
Research Core
UCSF



Josie Ni
Division of
Gastroenterology,
Perelman School of
Medicine
**University of
Pennsylvania**



Dana Graves
Professor, Department of
Periodontics
Penn Dental Medicine



Andrew Gewirtz
Professor, Institute of
Biomedical Science
Georgia State University



Michelle
McGuire
Professor
**Washington State
University**



"This is a useful event because it's a focused meeting in which I can actually meet up with some of the top names in Microbiome and do my networking."

Professor of Microbiome Research, Cardiff University

2017

SPEAKER FACULTY



Jo Sliman
Chief Medical Officer
Synthetic Biologics



Emeran Mayer
Director, Oppenheimer
Center for Neurobiology of
Stress; Division of Digestive
Diseases, David Geffen
School of Medicine
UCLA



Andreas Bäumlér
Professor
**UC Davis School of
Medicine**



Gregory Buck
Professor, Director,
Center for the Study of
Biological Complexity
VCU



Larry Weiss
Chief Medical Officer
AOBiome



Travis Whitfill
Chief Science Officer
Azitra Inc.



Ricardo Teles
Professor and Chair,
Department of Periodontics
**University of
Pennsylvania**



Flavia Teles
Associate Professor,
Department of Microbiology
**University of
Pennsylvania**



Professor Katrine
Whiteson
Assistant Professor of
Molecular Biology and
Biochemistry
University California



Iliyan D. Iliev
Assistant Professor
of Microbiology &
Immunology in
**Medicine Weill Cornell
Medicine**



Scott Bultman
Associate Professor,
Department of Genetics
**University of North
Carolina**



Larry J. Forney
Professor, Department of
Biological Sciences
University of Idaho



David Pride
Associate Professor of
Pathology and Medicine
**University Of California,
San Diego**



Colleen Cutcliffe
CEO
Whole Biome



Johan van
Hylckama Vlieg
Vice President Microbiome
& Human Health Innovation
Chr. Hansen A/S



Lada Rasochova
CEO
Dermala Inc.



Nikole E. Kimes
Co-Founder and Vice
President
Siolta Therapeutics



John Hambor
Director, Research Beyond
Borders
Boehringer Ingelheim

Get INVOLVED

MEETING MOJO

Establishing multi-disciplinary collaboration is at the forefront of the Microbiome Congress. Therefore, in addition to the networking opportunities during event breaks and talks, our 'MEETING MOJO' platform allows you to create a bespoke meeting schedule, ensuring you connect with the individuals most relevant to your interests.

REGISTER TODAY

RISING STAR TRAVEL GRANT

\$250 Travel Grants are available for FIVE young researchers (defined as having completed their PhD within the last 5 years). To be considered for one of the Rising Star Travel Grants, you must submit an abstract before 15th December 2017.

PLEASE VISIT THE WEBSITE TO ACCESS THE SUBMISSION FORM

INNOVATION STAGE

Academics and early stage start-ups are invited to present innovations that they are looking to commercialize.

Whether you are looking for investment or just want an expert opinion on next steps in your commercialization journey, this platform will be valuable for you.

The platform allows FOUR presenters to share as much or as little information around their innovation as they feel comfortable, and receive tips and advice from a panel of expert investors, consultants, pharmaceutical companies, lawyers and successful start-ups, as well as input from the audience.

APPLY HERE

POSTER PRESENTATION

If you are looking to highlight your recent work to the wider microbiome community, the dedicated poster session is a great way to get your research noticed and further involve yourself with the congress.

In order to present a poster, you need to be registered as a delegate. Poster space is assigned on a first come, first served basis. Your presentation will be displayed in a dedicated poster area, while presentation sessions will take place both in the breaks and alongside sessions at prescheduled times.

Deadline: 19th January 2018


PLEASE VISIT THE WEBSITE TO ACCESS THE SUBMISSION FORM

COMMERCIALIZATION SURGERY

Attendees are invited to pose questions and seek advice from a panel of industry leaders who have been through the commercialization process.

SUBMIT YOUR QUESTIONS





Microbiome Congress

PAST ATTENDEES

A Sample of Past Attendees in the Microbiome Congress Series



UPCOMING EVENTS FROM THE MICROBIOME PORTFOLIO



21-22 March
KANSAS CITY



22-23 May
LONDON



November 27-29
LONDON



November 2018
LONDON

13.30 REGISTRATION

14.00 An Introduction to Commercializing the Microbiome

14.20 Intellectual Property and Patenting

14.40 Transitioning from Academia to Business

Nikole E. Kimes, Co-Founder and Vice President, [Siolta Therapeutics](#)

15.00 INNOVATION STAGE.

Academics and start-ups are invited to present research and innovations that they are looking to commercialize in the future. Whether you are looking for investment or just want an expert opinion on the next steps in your commercialization journey, this platform will be valuable for you.

Within the microbiome community, there is lots of discussion around protecting and patenting ideas, but here at the North American Microbiome Congress, we understand that inspiration and innovation comes from not only protecting ideas, but also connecting them.

This platform allows FOUR presenters to share as much or as little information around their innovation as they feel comfortable, and receive tips and advice from a panel of expert investors, consultants, pharmaceutical companies, lawyers and successful start-ups, as well as input from the audience.

This is the perfect platform for discovering new collaboration opportunities.

You can submit an application to be considered at: www.humanmicrobiomecongress.com

15.40 AFTERNOON NETWORKING AND PRIVATE PRE-SCHEDULED MEETINGS

15.40 Private Prescheduled Meeting

16.00 Private Prescheduled Meeting

16.20 Private Prescheduled Meeting



16.40 PANEL: Commercializing the Microbiome - Lessons to be Learnt

David H. Donabedian, Co-founder & CEO, [Axial Biotherapeutics](#)

Travis Whitfill, Chief Science Officer, [Azitra Inc.](#)

Johan van Hylckama Vlieg, Vice President Microbiome & Human Health Innovation, [Chr. Hansen A/S](#)

John Hambor, Director, Research Beyond Borders, [Boehringer Ingelheim](#)

17.10 COMMERCIALIZATION SURGERY:

Attendees are invited to pose questions and seek advice from a panel of industry leaders who have been through the commercialization process. Please submit a question during the registration process or email events@kisacoresearch.com using the subject line 'Commercialization Surgery'

17.30 END OF COMMERCIALIZATION DAY

17.30 Private Prescheduled Meeting

17.50 Private Prescheduled Meeting

18.10 Private Prescheduled Meeting



"A real state of the art update of a rapidly changing and exciting area."

Consultant General and Colorectal Surgeon, Vale Healthcare

Agenda DAY ONE

6TH FEBRUARY 2018

08:30 **REGISTRATION**

08:55 **Chairman's Opening Remarks**

09:00 **Title TBC**

[John Hambor](#), Director, Research Beyond Borders, [Boehringer Ingelheim](#)

09:30 **Protection of the Gut Microbiome: Innovative Solutions to Dysbiosis and Antibiotic Resistance**

[Jo Sliman](#), Chief Medical Officer, [Synthetic Biologics](#)

10:00 **Implications of Probiotics in Obesity**

[Maria Marco](#), Associate Professor, Food Science and Technology, [UC Davis](#)

10:30 **MORNING NETWORKING BREAK**

10.30 Private Prescheduled Meeting

10.50 Private Prescheduled Meeting



11:10 **PANEL: Protecting the Gut Microbiota**

[Jo Sliman](#), Chief Medical Officer, [Synthetic Biologics](#)

[Professor Mark Pimentel](#), Director of GI Motility Program, [Cedars Sinai](#)

CONCURRENT SESSIONS BEGIN

BLUE TRACK

11:40 **Influence of Modifiable Factors on the Vaginal Microbiota and Preterm Birth**

[Mary Regan](#), Associate Professor, [University of Maryland School of Nursing](#)

12:10 **The Gut-Brain Axis**

[Sarkis Mazmanian](#), Professor of Microbiology; Investigator, Heritage Medical Research Institute. B.S., [University of California](#)

12:40 **NETWORKING LUNCH**

13.10 – Private Prescheduled Meeting

13.30 – Private Prescheduled Meeting

13.50 – Private Prescheduled Meeting



14:10 **Breast Milk Interactions with the Commensal Bacteria that Colonize the Infant Gut Microbiome**

[David Sela](#), Assistant Professor in the Department of Food Science, [University of Massachusetts](#)

GREEN TRACK

Rising Star Poster Presentation

Five young researchers (defined as those who have completed a PhD in the last 5 years) who were chosen to receive one of the \$250 Travel Grants will each present their poster on the main stage.



Inflammation and Diabetes as They Relate to Periodontal Disease

[Dana Graves](#), Professor, Department of Periodontics, [Penn Dental Medicin](#)

Agenda DAY ONE

6TH FEBRUARY 2018

14.40	Microbial Biomarkers of Periodontal Disease Progression Ricardo Teles , Professor and Chair, Department of Periodontics, University of Pennsylvania	Human microbiome and the next generation treatments for chronic skin diseases Lada Rasochova , CEO, Dermala Inc.
15.10	From microbial homeostasis to oral dysbiosis: the good, the bad and the unknown Flavia Teles , Associate Professor, Department of Microbiology, University of Pennsylvania	Role of viruses in the human microbiome. David Pride , Associate Professor of Pathology and Medicine, UNIVERSITY OF CALIFORNIA, SAN DIEGO
15.40	Understanding How Human-Associated Microbial and Viral Communities Affect Health Professor Katrine Whiteson , Assistant Professor of Molecular Biology and Biochemistry, University California	Investigating the Role of Dietary Fiber, Gut Microflora, and Epigenetic Events that Protect Against Colorectal Cancer Scott Bultman , Associate Professor, Department of Genetics, University of North Carolina
16.10	AFTERNOON NETWORKING BREAK	
16.30	The Vaginal Microbiome in Preterm Birth Gregory Buck , Professor, Director, Center for the Study of Biological Complexity, VCU	
16.50	Canary in the Coalmine: Neonatal Gut Microbiome and the Development of Childhood Atopy and Asthma Susan Lynch , Director, Colitis and Crohn's Disease Microbiome Research Core, UCSF	
17.20	Exploring Microbiome Interventions in Type 2 Diabetic Patients Colleen Cutcliffe , CEO, WholeBiome	
17.30	CLOSE OF CONFERENCE DAY ONE 18.00 – Private Prescheduled Meeting 18.20 – Private Prescheduled Meeting 18.40 – Private Prescheduled Meeting 19.00 – Private Prescheduled Meeting	



Agenda DAY TWO

7TH FEBRUARY 2018

08:30 REGISTRATION

08:55 Chairman's Opening Remarks

09:00 Illumination of gut microbiome function using multi-omics

Janet Jansson, Division Director of Biological Sciences, Pacific Northwest National Laboratory

09:30 One Health – The Importance of Collaboration

Bruce Taillon, Director External Innovation, Elanco

10:00 The Intestinal Epithelium and Chronic Inflammation

Andrew Gewirtz, Professor, Institute of Biomedical Science, Georgia State University

10:30 MORNING NETWORKING BREAK

11:00 DISCUSSION: The Strength and Relevance of Models in Translating the Microbiome

Scott Bultman, Associate Professor, Department of Genetics, University of North Carolina

TBC

TBC

11:30 The Regulatory Challenge for Approving Microbiome Products to meet the unmet medical needs of patients

Jim Weston, Vice President and Head of Regulatory Affairs, Seres Therapeutics

12:00 Discovery and Production of Anaerobic Bacteria – Making the Third Wave of Probiotics a Reality

Johan van Hylckama Vlieg, Vice President Microbiome & Human Health Innovation, Chr. Hansen A/S

12:40 NETWORKING LUNCH

13:10 Private Prescheduled Meeting

13:30 Private Prescheduled Meeting

13:50 Private Prescheduled Meeting



CONCURRENT SESSIONS BEGIN

BLUE TRACK

14:10 Ammonia Oxidizing Bacteria - A Live Topical Therapeutic

Larry Weiss, Chief Medical Officer, AOBiome

14:40 Presentation TBC

GREEN TRACK

The Gut Brain Axis in Human Infants

Rebecca Santelli, Associate Professor, UNC School of Medicine

Gut microbiota and IBD: causation or correlation?

Josie Ni, Division of Gastroenterology, Perelman School of Medicine, University of Pennsylvania

Agenda DAY TWO

7TH FEBRUARY 2018

15.10

Gut mycobiome shapes host immunity and inflammatory disease

Iliyan D. Iliev, Assistant Professor of Microbiology & Immunology in [Medicine Weill Cornell Medicine](#)

Is Human Milk Mother Nature's Quintessential Smart Food for Neonatal Gastrointestinal Microbial Colonization?

Michelle McGuire, Professor, [Washington State University](#)

15.40

AFTERNOON NETWORKING BREAK

15.40 – Private Prescheduled Meeting

16.00 – Private Prescheduled Meeting



16.20

Healthy Guts Exclude Oxygen

Andreas Bäumler, Professor, [UC Davis School of Medicine](#)

16.50

Words matter: How myths come to exist and persist in microbiome science

Larry J. Forney, Professor, Department of Biological Sciences, [University of Idaho](#)

17.20

'Bugs as drugs' for the skin: a novel, microbiome-based platform for treating skin disease

Travis Whitfill, Chief Science Officer, [Azitra Inc](#)

17.50

CLOSE OF CONFERENCE DAY TWO



"This was an excellent focused event for the microbiome community, whether biotech, pharma or investor, to exchange views, speculate on the future and network."

CHIEF EXECUTIVE OFFICER, MICROBIOTICA LTD



"Excellent meeting and great networking opportunity."

Venture Partner and Investment Advisor for Microbiome, Seventure Partners

Congress SPONSORS

HEADLINE SPONSOR:



Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage company developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The company's lead gut microbiome-focused programs poised for Phase 3 development include, SYN-010 a proprietary, modified-release formulation of lovastatin lactone intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004 (ribaxamase), a first-in-class oral enzyme designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics for the prevention of *C. difficile* infection, antibiotic-associated diarrhoea (AAD) and the emergence of antibiotic resistant organisms. The company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit www.syntheticbiologics.com.



Evolve BioSystems is dedicated to developing the next generation of products to establish, restore, and maintain a healthy newborn gut microbiome. Building on a decade of expertise in the partnership between the infant gut microbiome and human breast milk. Evolve BioSystems is solving newborn gut dysbiosis, or an imbalance of beneficial bacteria, through microbiome-based interventions in both human and animal health.



Microbiome Labs was originally established as Physicians Exclusive in 2013 as an organization focused on providing probiotic bacteriotherapy. In the past several years our business model has grown and so has public awareness for gut health issues. Microbiome Labs comes to you as an all inclusive resource center designed to address the needs of physicians and health care practitioners.



Anaerobe Systems Anaerobe Systems produces the only true Pre-Reduced Anaerobically Sterilized (PRAS) plated and tubed culture media in the USA. Founded over 35 years ago, for scientists by scientists, Anaerobe Systems has discovered practical and efficient ways to maximize anaerobic culture techniques. Using a patented procedure, we prepare and package media in an oxygen-free environment from sterilization to packaging. Our product is shipped to you in anaerobic packages. Exposure of specimens to oxygen is eliminated at every step to ensure accurate results. The benefits of such care are greatly reduced time in preparation and handling of cultures and substantially increased recovery of anaerobes. This improved productivity will be visibly apparent within 18 to 24 hours of incubation.



M2P Labs Based in Baesweiler, Germany (near Aachen), the company was founded in November 2005 as a spin-off of RWTH Aachen University. The company focuses on microreaction and automated solutions for screening and bioprocess development. Our commercialized products are the BioLector, the BioLector Pro, and the FlowerPlate, which provide an intelligent micro fermentation platform. This proprietary technology empowers the biotechnology, chemical, and pharmaceutical industries to increase the number and the information content of microbial experiments (aerobic, microaerophilic, and strictly anaerobic). It enables customers to conduct experiments with high efficiency and excellent quality in microscale at low costs. With the RoboLector, the company also enables the automated fermentation of the whole bioprocess, with the specific integration of the BioLector tool into a liquid handling system.

Sponsorship

OPPORTUNITIES

Far from the typical 'meet-and-greet' exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with the conference will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts.

CONTACT US: Ask us about the different ways you can get involved. Contact **Mark Gavhure** to find out more about each package by emailing events@kisacoresearch.com or by calling: +44 (0)20 3696 2925.

VENUE & REGISTRATION



HILTON SAN DIEGO RESORT

1775 EAST MISSION BAY DRIVE
SAN DIEGO, CA 92109
United States of America

TO BOOK ACCOMMODATION

Telephone: 877-313-6645

Rates ends - January 10, 2018

Standard Room – Single/Double - \$189

PRICING INFORMATION

PASS TYPE	Early Bird 1 Pricing through November 17th	Early Bird 2 Pricing through December 15th	STANDARD PRICING
Academics, Students & Post-Doctoral Researchers	\$699 (Includes Commercialization Day)	\$899 (Includes Commercialization Day)	\$1099 (Includes Commercialization Day)
Pharmaceutical and Biotech	\$1,299	\$1,499	\$1,699
Service Providers, Vendors	\$1,799	\$1,999	\$2,199
Commercialization Day	\$400		
Poster Session	\$50		

Register Now ▶

Payment Terms for the Microbiome Conference:

- Please note that a \$79 processing fee will apply to any invoices requested.
- * You must email us a signed letter from the Hospital / Clinic Supervisor or University / Laboratory with confirmation of your status upon payment
- All Prices are in USD

- All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
- All discount offers cannot be combined with any other offer.
- Please view our Cancellation Policy.

**Apply to the
Innovation Stage**

APPLY NOW ▶

**Submit To The
Poster Session**

SUBMIT NOW ▶

**Apply For A Rising
Star Travel Grant**

APPLY NOW ▶

**Submit a Question to the
Commercialization Surgery**

SUBMIT NOW ▶